| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rebaudioside F (Reb F) primarily targets and binds to the human sweet taste receptor, a heterodimeric G protein-coupled receptor composed of T1R2 and T1R3 subunits. Research on steviol rebaudiosides has demonstrated that these compounds can bind to four distinct sites on the sweet taste receptor complex, including the Venus Flytrap Domains (VFD2 and VFD3) and the transmembrane domains (TMD2 and TMD3) . The binding of Reb F to these multiple sites triggers a signal transduction pathway involving G protein activation, leading to the perception of sweetness.
|
|---|---|
| ln Vitro |
The primary in vitro activity of Rebaudioside F (Reb F) has been characterized through its interaction with the sweet taste receptor. Cell-based assays using HEK-293 cells or other heterologous systems overexpressing T1R2/T1R3 and promiscuous G proteins are commonly used to measure receptor activation via calcium ion mobilization or dynamic mass redistribution . In addition, in vitro fermentation studies have been conducted using human fecal incubations to investigate the metabolism of steviol glycosides. These studies demonstrate efficient deglycosylation and hydrolysis of Reb F and other rebaudiosides in the presence of colonic microbiota, converting them to the final stable metabolite steviol . Reb F also exhibits prebiotic-like properties by promoting the growth of beneficial gut bacteria such as Bifidobacterium animalis subsp. lactis .
|
| ln Vivo |
As a member of the steviol glycoside family, Reb F is expected to share similar biological properties with other rebaudiosides. Beyond its value as a sweetener, steviol glycosides have demonstrated therapeutic effects against several diseases, including diabetes mellitus, hypertension, inflammation, obesity, and tooth decay . These compounds are not accumulated in the body, as metabolized components essentially leave the body . No acute or subacute toxicity has been observed in animal studies .
|
| Enzyme Assay |
The binding of Rebaudioside F (Reb F) to the sweet taste receptor has been investigated using a combination of experimental and computational approaches. Studies have employed heterologous cell-based assays with HEK-293 cells overexpressing the T1R2/T1R3 heterodimer and promiscuous G proteins. Receptor activation is typically measured by monitoring changes in intracellular calcium concentration as a second messenger in the sweet taste downstream signaling pathway . For membrane protein stabilization, tools such as DIBMA (diisobutylene-maleic acid) Glycerol and Rho1D4-MagBeads have been used to preserve the native lipidic environment of the receptors . Computational docking studies have revealed that steviol rebaudiosides can bind to nine different binding pockets on the sweet taste receptor, with binding occurring at VFD2, VFD3, TMD2, and TMD3 domains .
|
| Cell Assay |
Rebaudioside F (Reb F) has been evaluated in cell-based assays using HEK-293 cells stably transfected with the human T1R2/T1R3 sweet taste receptor. In these assays, cells are loaded with calcium-sensitive fluorescent dyes, and upon stimulation with Reb F, the resulting intracellular calcium release is measured using fluorescence plate readers . The concentration of calcium ions serves as an indicator of sweet taste receptor activation. This cell-based approach has been widely used to characterize the potency and efficacy of various steviol glycosides. Additionally, dynamic mass redistribution (DMR) assays have been employed to measure receptor activation in stable clones overexpressing T1R2/T1R3, allowing for effective coupling of the receptors to endogenous G proteins without the need for promiscuous G protein co-expression .
|
| Animal Protocol |
Toxicological assessments of steviol glycosides, including Reb F, have been conducted and indicate no acute or subacute toxicity, nor teratogenic, mutagenic, or carcinogenic effects . The metabolized components essentially leave the body without accumulation . However, specific study designs, dosing regimens, administration routes, or species details for Reb F alone are not provided in the current search results.
|
| ADME/Pharmacokinetics |
Rebaudioside F (Reb F) is not absorbed intact in the gastrointestinal tract. Instead, it undergoes efficient deglycosylation and hydrolysis by the colonic microbiota (e.g., Bacteroides species) to the final stable metabolite, steviol . This metabolic process has been demonstrated in vitro using human fecal homogenate incubations, where Reb F and other rebaudiosides (including A, B, C, D, E, and M) are efficiently hydrolyzed . After absorption, steviol is glucuronidated in the liver to form steviol glucuronide, which is then excreted primarily in the urine and partly via bile into the feces . There is no accumulation of these compounds in the body .
|
| Toxicity/Toxicokinetics |
Rebaudioside F (Reb F) has been extensively evaluated for safety. Studies have shown that steviol glycosides, including Reb F, are not teratogenic, mutagenic, or carcinogenic and cause no acute or subacute toxicity . The compound is generally recognized as safe for human consumption as a food ingredient and sugar substitute. The microbial hydrolysis of Reb F in the colon leads to the production of steviol, which is efficiently eliminated from the body without accumulation . No significant adverse effects have been reported at recommended dietary intake levels. The compound is intended for use as a sweetener in foods, beverages, and medicines.
|
| References | |
| Additional Infomation |
Rebaudioside F (Reb F) is one of the minor steviol glycosides naturally present in the leaves of Stevia rebaudiana, with its structure characterized by the presence of a xylose moiety. Beyond its value as a high-intensity sweetener (250-300 times sweeter than sucrose), steviol glycosides including Reb F possess therapeutic effects against several diseases such as cancer, diabetes mellitus, hypertension, inflammation, cystic fibrosis, obesity, and tooth decay . The compound exhibits anti-inflammatory, antihypertensive, antihyperglycemic, antitumor, antidiarrheal, diuretic, non-cariogenic, and immunomodulatory properties . Reb F is also being explored for its prebiotic potential, as in vitro studies have shown it can promote the growth of beneficial gut bacteria such as Bifidobacterium animalis subsp. lactis . The compound is commercially used as a sugar substitute and has been approved for use in foods and beverages worldwide.
It has been reported that stevia (Stevia rebaudiana) contains rebaudioside F, and relevant data is available. See also: Stevia leaf (partial). |
| Molecular Formula |
C43H68O22
|
|---|---|
| Molecular Weight |
936.9868
|
| Exact Mass |
936.42
|
| CAS # |
438045-89-7
|
| PubChem CID |
72941817
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.7
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
65
|
| Complexity |
1710
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)(C)C(=O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O
|
| InChi Key |
HYLAUKAHEAUVFE-AVBZULRRSA-N
|
| InChi Code |
InChI=1S/C43H68O22/c1-17-11-42-9-5-22-40(2,7-4-8-41(22,3)39(57)64-37-32(56)29(53)26(50)20(13-45)60-37)23(42)6-10-43(17,16-42)65-38-34(63-35-30(54)24(48)18(47)15-58-35)33(27(51)21(14-46)61-38)62-36-31(55)28(52)25(49)19(12-44)59-36/h18-38,44-56H,1,4-16H2,2-3H3/t18-,19-,20-,21-,22+,23+,24+,25-,26-,27-,28+,29+,30-,31-,32-,33+,34-,35+,36+,37+,38+,40-,41-,42-,43+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate
|
| Synonyms |
Rebaudioside F; 438045-89-7; (-)-Rebaudioside F; Rebaudioside F, (-)-; 9JYN4KSY90; .
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Methanol/MeOH: ~1 mg/mL (1.1 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0672 mL | 5.3362 mL | 10.6725 mL | |
| 5 mM | 0.2134 mL | 1.0672 mL | 2.1345 mL | |
| 10 mM | 0.1067 mL | 0.5336 mL | 1.0672 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
